The last two decades have seen ground-shifting changes in the epidemiology, genetics, diagnosis and management of renal cancer. Advances in diagnosis have led to many tumours being identified at an asymptomatic stage. There have also been parallel advances in treatment, such as nephron sparing procedures and radiologically guided ablative procedures. However, these changes have brought with them dilemmas such as our ability to evaluate the nature...